Article Text

Download PDFPDF

295 Accumulation of 53BP1 in circulating tumor cells during treatment with eribulin identifies chemotherapy-responsive metastatic breast cancer patients
Free
  1. Fabienne Schochter1,
  2. Kim Werner1,
  3. Cäcilia Köstler2,
  4. Volkmar Müller3,
  5. Hans Neubauer4,
  6. Tanja Fehm5,
  7. Thomas WP Friedl1,
  8. Bernhard Polzer2,
  9. Wolfgang Janni1 and
  10. Lisa Wiesmüller1
  1. 1Ulm University; Department of Obstetrics and Gynecology
  2. 2Fraunhofer-Institute for Toxicology and Experimental Medicine; Division of Personalized Tumor Therapy
  3. 3Universitätsklinikum Hamburg-Eppendorf; Klinik und Poliklinik für Gynäkologie; Department of Gynecology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
  4. 4Heinrich-Heine-University of Düsseldorf; Department of Obstetrics and Gynecology; Life Science Center
  5. 5Universitätsklinikum Düsseldorf; Klinik für Frauenheilkunde und Geburtshilfe; Department of Obstetrics and Gynecology, University of Duesseldorf, 40225 Duesseldorf, Germany

Abstract

Introduction/Background Evidence suggests that the DNA end-binding protein p53-binding protein 1 (53BP1) expression in breast cancer is associated with poor prognosis, especially in triple-negative breast cancer (TNBC). Circulating tumor cells (CTCs) provide accessible ‘biopsy material’ to track cell traits and functions and their alterations during treatment.

Methodology We prospectively monitored the 53BP1 status, as a parameter for intact DNA damage response, in CTCs from 63 metastatic breast cancer (MBC) patients with HER2- CTCs before, during, and at the end of chemotherapeutic treatment with Eribulin in the DETECT-IV trail. Nuclear 53BP1 staining and genomic integrity were evaluated by immunocytochemical and whole-genome-amplification-based polymerase chain reaction (PCR) analysis. We used mean 53BP1 scores in CTC samples as dividing criteria, i.e. compared patients with 53BP1 scores <50% and ≥50%. We analyzed PFS of the patients from these two groups using scores obtained with samples at different time points during the study.

Results We found a decline of mean CTC numbers from baseline to 12 weeks of treatment but a dramatic rise at the final visit due to disease progression in 10/13 of the cases (mean CTC-values at baseline: 18, 2nd visit: 2, final visit: 118). Comparative analysis of CTCs from patients with 15 triple-negative and 48 hormone receptor positive tumors revealed elevated 53BP1 levels in CTCs from patients with HR+ metastases, particularly following chemotherapeutic treatment. Kaplan–Meier analysis between nuclear 53BP1-positivity in CTCs and progression-free survival (PFS) revealed an increasing association during chemotherapy until last examination (p=0.065).

Conclusion Our data suggest that 53BP1 detection in CTCs could be a useful marker to capture dynamic changes of chemotherapeutic responsiveness in triple-negative and HR+ MBC.

Disclosures FSch received speaker honoraria and a travel grant from Roche, Novartis, Pfizer and Lilly.

VM speaker honoraria from Amgen, Astra Zeneca, Celgene, Daiichi-Sankyo, Eisai, Pfizer, MSD, Novartis, Roche, Teva, and consultancy honoraria from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi-Sankyo, Eisai, Lilly, Tesaro, and Nektar, as well as institutional research support from Novartis, Roche, Seattle Genetics, and Genentech. Otherwise, no potential conflicts of interests were disclosed by the authors.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.